Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAE005 + afuresertib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Laekna
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous
01
Overview
This is an experimental **three-drug combination therapy** consisting of **LAE005**, **afuresertib**, and **nab-paclitaxel**. - **LAE005**: Little publicly available information; presumed to be an investigational compound from Laekna, possibly with antineoplastic properties, mechanism not publicly disclosed as of September 2025. - **Afuresertib**: A small molecule, orally administered, ATP-competitive, pan-AKT kinase inhibitor developed as an antineoplastic agent. It inhibits AKT1, AKT2, and AKT3, disrupting the PI3K/AKT signaling pathway, which is important in cancer cell survival, proliferation, and drug resistance[1][3][4]. - **Nab-paclitaxel**: Nanoparticle albumin-bound form of the antineoplastic agent paclitaxel; functions by stabilizing microtubules and inhibiting cell division, used in various solid malignancies. This combination is under clinical investigation for **advanced or resistant cancers**, particularly those with aberrant PI3K/AKT signaling or where AKT inhibition improves response to taxane chemotherapy.
- Other names
- albumin-bound paclitaxel
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)CD274 (Programmed cell death protein 1 ligand 1)PKA (Cyclic amp-dependent protein kinase)PKG (cGMP-dependent protein kinase I alpha)PKG1β (cGMP-dependent protein kinase 1 beta)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on LAE005 + afuresertib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAE005 + afuresertib + nab-paclitaxel.